NCT05249322

Brief Summary

The pandemic forced us to develop home follow-up for patients with chronical diseases . In the same time, the new era of treatment for cystic fibrosis considerably improves the health of patients with this pathology. This study aims to assess the satisfaction of patients and care providers for an alternated follow-up between tele-consults and in-hospital consults during one year for patients with cystic fibrosis treated by Kaftrio® since at least one year and stable.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 27, 2022

Completed
25 days until next milestone

First Posted

Study publicly available on registry

February 21, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

March 31, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2024

Completed
Last Updated

September 28, 2023

Status Verified

September 1, 2023

Enrollment Period

2 years

First QC Date

January 27, 2022

Last Update Submit

September 26, 2023

Conditions

Keywords

tele-medicinecystic fibrosisalternate follow-up

Outcome Measures

Primary Outcomes (1)

  • Change in Patients and care providers satisfaction after one year of alternated follow-up (hospital Consults and Tele-consult)

    Satisfaction of patients and care providers for the follow-up by the Client-Satisfaction-Questionnaire (CSQ-8 for patients and CSQ-3 for care-provider). For the CSQ-8 the minimum value is 8 and the maximum value is 32. There is three levels: Low satisfaction (8-20), medium satisfaction (21-26) and high satisfaction (27-32) .

    Measured at inclusion and after one year of follow up.

Secondary Outcomes (7)

  • Patients and care providers satisfaction for tele consultation

    Measured after tele-consult (at 6 month M+6 and at 12 month M+12)

  • Comparison between FEV1 measured at the department's respiratory functional exploration center and FEV1 measured with the Spirobank ® during the same in-hospital visit.

    At inclusion, 6month and 12 month

  • effect on Patients and care providers quality of life

    Measured at inclusion and after one year

  • effect on Patients FEV1 (Forced expiratory volume)

    Measured at inclusion and after one year

  • effect on Patients antibiotic cure number

    Measured at inclusion and after one year

  • +2 more secondary outcomes

Study Arms (1)

Follow-up alternating between face-to-face consultation and teleconsultation every three months

EXPERIMENTAL

Patients of this arm will be followed alternating between face-to-face consultation and teleconsultation respecting the recommended frequency (every three months) during 12 months (M+3:teleconsultation - M+6:in-hospital consultation - M+9:teleconsultation - M+12 : in-hospital consultation)

Other: Follow-up alternating between face-to-face consultation and teleconsultation every three months.

Interventions

The intervention will be an alternate follow-up every three months with: * A tele-consult: with paramedical consult (with assistance for home-spirometry) and medical consult for about 1h30 in total, make with a HCL platform for telemedicine. * An usual in-hospital consult of about 1h30 with paramedical and medical consult.

Follow-up alternating between face-to-face consultation and teleconsultation every three months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with cystic fibrosis
  • Patients treated with Kaftrio® since one year
  • autonomous patients
  • patients without cognitive disorders
  • Patients voluntary for this follow up
  • patients with two tele-communication tools
  • patients with FEV1\>50%
  • patients with less of 2 antibiotics cure per year

You may not qualify if:

  • all transplanted patients
  • Pregnant patients
  • Particular follow up needed in-hospital consult
  • Persons deprived of their liberty by a judicial or administrative decision
  • Persons subject to psychiatric care
  • Persons admitted to a health or social establishment for purposes other than research
  • Persons not affiliated to a social security scheme or beneficiaries of a similar scheme

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Lyon Sud

Pierre-Bénite, 69 495, France

RECRUITING

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, Diseases

Study Officials

  • Thomas VIDAL

    adult cystic fibrosis centre Lyon

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Isabelle Durieu, Pr

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 27, 2022

First Posted

February 21, 2022

Study Start

March 31, 2022

Primary Completion

March 31, 2024

Study Completion

March 31, 2024

Last Updated

September 28, 2023

Record last verified: 2023-09

Locations